C.E.M. Griffiths

Research interests

Publications

• Psoriasis

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(20)32549-6

• National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study

  BMJ · 2020 · https://doi.org/10.1136/bmj.m1590

• Clinical applications of machine learning algorithms: beyond the black box

  BMJ · 2019 · https://doi.org/10.1136/bmj.l886

• Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council

  Journal of the American Academy of Dermatology · 2019 · https://doi.org/10.1016/j.jaad.2019.08.026

• Clinical and genetic differences between pustular psoriasis subtypes

  Journal of Allergy and Clinical Immunology · 2018 · https://doi.org/10.1016/j.jaci.2018.06.038

• Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

  Journal of the American Academy of Dermatology · 2017 · https://doi.org/10.1016/j.jaad.2016.11.041

• Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31191-1

• Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

  Journal of the American Academy of Dermatology · 2015 · https://doi.org/10.1016/j.jaad.2015.03.049

• Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

  The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)60125-8

• Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1314258

• Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

  Nature Genetics · 2012 · https://doi.org/10.1038/ng.2467

• Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

  Journal of Investigative Dermatology · 2012 · https://doi.org/10.1038/jid.2012.339

• Definition of treatment goals for moderate to severe psoriasis: a European consensus

  Archives of Dermatological Research · 2010 · https://doi.org/10.1007/s00403-010-1080-1

• European S3‐Guidelines on the systemic treatment of psoriasis vulgaris

  Journal of the European Academy of Dermatology and Venereology · 2009 · https://doi.org/10.1111/j.1468-3083.2009.03389.x

• Pathogenesis and clinical features of psoriasis

  The Lancet · 2007 · https://doi.org/10.1016/s0140-6736(07)61128-3

• Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

  The Lancet · 2005 · https://doi.org/10.1016/s0140-6736(05)67566-6

• Biological therapies in the systemic management of psoriasis: International Consensus Conference

  British Journal of Dermatology · 2004 · https://doi.org/10.1111/j.1365-2133.2004.06070.x

• An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis

  Archives of Dermatology · 2003 · https://doi.org/10.1001/archderm.139.6.719

Current projects

No projects listed.